Donald J. Zurbay Joins Avedro’s Board Of Directors

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro, Inc., an ophthalmic pharmaceutical and medical device company and the world leader in corneal remodeling, today announced that Donald J. Zurbay has been elected to its board of directors.

“I’m thrilled to be joining Avedro’s board of directors and look forward to contributing to the business as they continue to execute their plans in expanding both in the US and internationally”

A veteran finance executive with more than 27 years in financial operations and accounting, Mr. Zurbay is the former vice president and chief financial officer (CFO) of St. Jude Medical, Inc., a Fortune 500 multi-national medical device company. During his tenure at St. Jude Medical, Mr. Zurbay helped guide the company through significant growth and expansion, including nineteen acquisitions, and ultimately the recent transaction to sell St. Jude Medical to Abbott for $25 billion.

“Don is an accomplished business leader with a proven track record of developing strategy and driving execution for business growth. He will be a superb advisor to Avedro and we are pleased to welcome him to the Board,” said Reza Zadno, Ph.D., chief executive officer of Avedro. “Don’s guidance will be indispensable as we continue to expand our ability to deliver innovative products that dramatically improve the lives of patients with keratoconus and develop new and innovative cross-linking applications that help reduce the need for eyeglasses and contact lenses.”

“I’m thrilled to be joining Avedro’s board of directors and look forward to contributing to the business as they continue to execute their plans in expanding both in the US and internationally,” said Mr. Zurbay.

About Avedro, Inc.
Avedro is a privately held pharmaceutical and medical device company and the world leader in corneal remodeling. Avedro’s patented cross-linking technology, consisting of drug formulations and medical devices, are approved for sale in numerous countries around the globe. In the United States the company sells an orphan drug, indicated for the treatment of progressive keratoconus, which was FDA approved in 2016. Avedro continues to develop proprietary cornea cross-linking products for the treatment of keratoconus, a sight-threatening disease, and for refractive correction.